Beijing Kangsheng Baichun Biotechnology Co., Ltd.

Primary objective: To compare the differences in absorption extent and rate of beraprost sodium tablets (specification: 40μg, test preparation) certified by Beijing Kangsheng Baichun Biotechnology Co., Ltd. and beraprost sodium tablets (specification: 40μg, reference preparation) certified by Takeda Teva Pharma Japan Inc. (Teva Pharma Japan Inc) in healthy subjects under the conditions of single administration on an empty stomach and after a meal. To evaluate whether the two are bioequivalent by the main pharmacokinetic parameters. Secondary objective: To evaluate the safety of beraprost sodium tablets by observing the safety indicators of healthy subjects after a single oral administration of the test preparation and the reference preparation.

Primary objective: To compare the differences in absorption extent and absorption rate between the pediatric faropenem sodium granules (specification: 0.05 g, calculated as C12H15NO5S) certified by Beijing Kangsheng Baichun Biotechnology Co., Ltd. and the pediatric faropenem sodium granules (specification: 0.05 g, calculated as C12H15NO5S) certified by Maruho Co., Ltd. in healthy Chinese population by using a single-dose, randomized, open, two-period crossover, fasting and postprandial oral administration design, and to evaluate bioequivalence. Secondary objective: To evaluate the safety of the test and reference preparations of the pediatric faropenem sodium granules (specification: 0.05 g, calculated as C12H15NO5S) in healthy subjects.